A Digital Therapeutic for Pain Relief through AI-Guided Visual Stimulation

项目摘要 蒲公英™成立于2020年，通过以下方式开发神经和精神疾病的数字疗法 通过眼睛与大脑互动。此SBIR的目标是设计和测试安全、有效和 以视觉刺激的形式进行的非上瘾止痛数字治疗。该平台将使用人工智能 智能(AI)和实时生物反馈，以“读”(解密)大脑信号和“写”(神经调节)大脑信号 具有快速变化的视觉刺激的大脑，由优化的图案、颜色和频率组成。这是 首次尝试使用人工智能引导的视觉刺激作为治疗疼痛的方法。2017年，1.91亿人中的1100万人 阿片类止痛药处方被滥用，35%与阿片类药物相关的死亡(近 17,000例)与这些处方有关。在寻找安全、有效的替代品方面，一系列 通过药理学、临床和数字化行为研究开发了阿片类药物节制干预措施 但没有一个平台被证明是完全成功的。蒲公英假设，生物的复杂性和变异性 疼痛需要一种治疗方法，模仿大脑本身处理和整合数据的方式 痛觉。通过其新的神经调节平台，使用人工智能来参数化 潜在有用的视觉信息，蒲公英将开发一种安全、低成本的数字疗法，患者可以 在智能手机或平板电脑上查看，可立即缓解疼痛。通过将刺激与不同领域的反应相关联 对于不同类型的疼痛，蒲公英也希望建立一张适用范围更广的疼痛感知地图。在第一阶段甲 将开发原型人工智能引导平台，可以合成新的刺激组合和 根据来自一系列生物传感器的反馈来优化它们；它们在减少对 然后，将在健康受试者身上测试诱发的疼痛。在第二阶段，蒲公英将把原型开发成 并测试止痛数字疗法的有效性和可推广性 随机对照试验。商业机会估计为59亿美元。

Project Summary Dandelion™ was founded in 2020 to develop digital therapeutics for neurologic and psychiatric disorders by interacting with the brain via the eyes. The goal of this SBIR is to design and test a safe, effective, and nonaddictive pain-relief digital therapeutic in the form of visual stimuli. The platform will use artificial intelligence (AI) and real-time biofeedback to “read” (decipher) brain signals and “write” to (neuromodulate) the brain with rapid-changing visual stimuli composed of optimized patterns, colors, and frequencies. This is the first attempt to use AI-guided visual stimuli as a treatment for pain. In 2017, 11 million of the 191 million prescriptions written for opioid pain medications were misused, and 35% of opioid-related deaths (nearly 17,000 cases) were connected to these prescriptions. In the search for safe, effective alternatives, a range of opioid-sparing interventions have been developed through pharmacologic, clinical, and digitized behavioral platforms but none has proved fully successful. Dandelion hypothesizes that the complexity and variability of pain demands a therapeutic approach that mimics the way the brain itself processes and integrates data for pain perception. Through its novel neuromodulatory platform, using artificial intelligence to parameterize potentially useful visual information, Dandelion will develop a safe, low-cost digital therapeutic that patients can view on a smartphone or tablet for immediate pain relief. By correlating stimulus with response across different types of pain, Dandelion also hopes to build a pain-perception map of wider applicability. In Phase I a prototype AI-guided platform will be developed that can synthesize novel stimulation combinations and optimize them based on feedback from an array of biosensors; their efficacy in reducing the perception of induced pain will then be tested in healthy subjects. In Phase II, Dandelion will develop the prototype into a commercially available product and test the pain-relief digital therapeutic for efficacy and generalizability in randomized controlled trials. The commercial opportunity is estimated to be $5.9 billion.